Add Lupin at lower levels: Sachin Shah

Sachin Shah - Fund Manager at Emkay Investment told CNBC-TV18, "Lupin is trading at about 30 times its March 15 numbers. The sense that we are getting after the analyst meet and bring all research reports, it is clear that the FY16 is going to be bit of a subdued year in terms of their earnings growth. May be just about low double digit or may be a single digit earnings growth is what we are looking at. FY17 could be much better because the company does expect a lot of approval from the Food and Drug Administration (FDA or US FDA) in terms of the new product to have them in the second half of FY16 or probably early FY17."

"Lupin is not a great value buy at this point in time. It is a big company; they have reached a particular size. Today they are almost a Rs 2,500 crore of profit company. My sense is that if somebody is taking a 3-5 years view it does make sense to start nibbling at this point in tine. Always keeping a room to add at lower levels. There could be a big kneejerk reaction so take advantage of that it is always prudent that one nibbles in to it in this kind of valuations," he said.